OP256 Recognising The Broader Value Of Vaccines In Health Technology Assessment: Worth A Shot?

Introduction The COVID-19 pandemic shows that the impact of effective vaccines extends well beyond vaccinated individuals and healthcare systems. Yet, these externalities are not typically considered in health technology assessments (HTA) which may underestimate vaccines’ broader value. We explored to what extent future relevant England might exhibit such Methods compared ten value elements an existing vaccine evaluation framework according Joint Committee on Vaccine Immunisation (JCVI) National Institute for Health Care Excellence's (NICE) guidelines. Using literature expert opinion we then explored, a selection with expected UK-launch within five years, each potentially show added Results Up unlikely be by JCVI or NICE, including patient carer productivity, enablement value, antimicrobial resistance transmission Of studied, 100 percent will generate at least one element is currently ignored; 60 80 increase vaccinee/patient productivity respectively. Conclusions There substantial gap between generation recognition HTA England. This lead undervaluation underutilization vaccines, leaving societies more vulnerable than needed when faced infectious diseases.